Stock Market Reviews

BBLG (Bone Biologics Corporation) News

Get the latest news, insights, and market updates on BBLG (Bone Biologics Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• BBLG Financials Show Company in Solid Shape
  By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively
  Mar 3, 2026 - $BBLG
• BBLG Approaching Crucial Stage
  By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively
  Feb 25, 2026 - $BBLG
• Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
  Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit
  Jan 8, 2026 - $BBLG
• Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
  Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by o
  Dec 23, 2025 - $BBLG
• BBLG Has Cash for Approval Push
  By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for the spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are
  Nov 17, 2025 - $BBLG
• Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
  BURLINGTON, Mass., September 04, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.
  Sep 4, 2025 - $BBLG
• BC-Most Active Stocks
  td class="col-issue">Next Technology Holding Inc.
  Sep 4, 2025 - $BBLG
• Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
  BURLINGTON, Mass., September 03, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.
  Sep 3, 2025 - $BBLG
• BBLG Has Solid Balance Sheet as Tests Progress
  By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are optimistic
  Aug 15, 2025 - $BBLG
• Bone Biologics Announces Closing of $5.0 Million Public Offering
  BURLINGTON, Mass., June 30, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of c
  Jun 30, 2025 - $BBLG